Bilal
Sabry
I build companies — and the software that runs them. I’m happiest in the overlap between the code, the deal, and the room where strategy gets set.
I’m a builder who never picked a lane. I write production software, I run the numbers that decide whether a business lives, and I sit in the rooms where the strategy gets set. The throughline is leverage — find the one decision that moves everything, then build the system that makes it repeatable.
I work across code, capital, and policy — and I’m most useful where they meet.
I’m Bilal — a founder, engineer, and trained economist. I finished a double degree at Berkeley in two and a half years, then went straight to where the stakes were real: advising a finance ministry through a sovereign default, running strategy and finance for a pharmaceutical manufacturer, and now building Krux AI.
I’m drawn to problems that sit between disciplines — where you have to write the code and model the deal and understand the policy. That overlap is where I do my best work, and it’s the reason I never picked a single lane.
Three things most people keep in separate rooms.
Build
I ship real software — Rust systems, production AI architecture, full-stack product. Not prototypes that demo well and break. Things with tests, CI, and users.
Operate
I run the numbers that decide whether a business lives — M&A, FP&A, deal structuring, restructuring. I’ve sat with a CEO and turned a services shop into a growth story, and I’ve lived in the board deck.
Think
I do the analysis that informs hard calls — sovereign fiscal policy under default, venture diligence, market strategy. Trained as an economist; comfortable where the stakes are real.
Turning 300-page pharma RFPs into regulator-grade proposals in minutes. Product, customers, and the raise — all at once.
krux.bio ↗A local-first research assistant in Rust that refuses to answer without span-level citations. Open source, 60+ tests, full CI.
Source ↗Why “RAG with footnotes” isn’t enough, and what auditable retrieval actually requires.
Read ↗Strategy and finance for a pharma CDMO, reporting to the CEO. M&A, capital strategy, and the board deck.


